Abbreviations & Acronyms ADT = androgen deprivation therapy ALP = alkaline phosphatase BMI = body mass index CAB = combined androgen blockade CAPRA = Cancer of the Prostate Risk Assessment CI = confidence interval CRPC = castration-resistant prostate cancer CSS = cancer-specific survival GS = Gleason score HR = hazard ratio IQR = interquartile range J-CAPRA = Japan Cancer of the Prostate Risk Assessment KCS-prostate = Korean Cancer Study of the Prostate LHRH = luteinizinghormone releasing hormone NCCN = National Comprehensive Cancer Network OS = overall survival PFS = progression-free survival PSA = prostate-specific antigen SE = standard error TNM = tumor-nodemetastasis Objectives: To investigate the progression to castration-resistant prostate cancer after primary androgen deprivation therapy, and to build a simple risk prediction model for primary androgen deprivation therapy patients based on the Japan Cancer of the Prostate Risk Assessment criteria. Methods: A total of 602 patients who received primary androgen deprivation therapy were entered into the Korean Cancer Study of the Prostate database. The effect of prognostic factors was determined by multivariate analysis. For each patient, the weight of all factors was totaled to give Korean Cancer Study-prostate scores; patients were divided into three risk groups according to their score. The probability of castrationresistant prostate cancer, cancer-specific survival and overall survival was estimated by Kaplan-Meier analysis. Results: On multivariate analysis for castration-resistant prostate cancer, the significant variables were initial prostate-specific antigen (>40 ng/mL; 1 point), biopsy Gleason score (≥9; 1 point), clinical N1 (1 point), and non-regional lymph node (1 point), bone (1 point) and visceral (1 point) metastasis. The Korean Cancer Study-prostate scoring model was calculated on a scale of 0-6 (0: low, 1-2: intermediate, ≥3: high risk). The risk groups stratified castration-resistant prostate cancer (P < 0.0001), cancer-specific survival (P < 0.0001) and overall survival (P < 0.0001) by Kaplan-Meier curve. The Korean Cancer Study-prostate model predicted castration-resistant prostate cancer with a c-index of 0.7242, cancer-specific survival with a c-index of 0.7036 and overall survival with a cindex of 0.5890. The 5-year estimated castration-resistant prostate cancer/cancer-specific death rates were 10.3%/6.3% in the low-risk group, 48.4%/22.2% in the intermediate-risk group and 81.7%/53.1% in the high-risk group. Conclusions: The Korean Cancer Study-prostate risk classification, a modified Japan Cancer of the Prostate Risk Assessment model, is a simple scoring model for predicting oncological outcomes after primary androgen deprivation therapy.
Introduction
Prostate cancer is the most common malignancy amongst patients in the USA, with 161 360 new cases estimated to arise in 2017. 1 After the widespread application of PSA testing, detection rates for prostate cancer increased rapidly; recently, however, there was a sharp decrease in detection because the US Preventive Services Task Force did not recommend PSA screening due to the risk of overdiagnosis. 2 After the decrease in PSA testing, the occurrence of advanced prostate cancer has been carefully monitored, and there have been no further decreases in detection rates. 1 ADT is the most common treatment for metastatic prostate cancer patients. According to the Korea Central Cancer Registry, 9.0% of prostate cancer showed distant disease at diagnosis. 3 ADT can also be utilized in cases of localized prostate cancer. Despite insufficient evidence that primary ADT for localized prostate cancer can improve survival, approximately 41% of men aged ≥66 years who were diagnosed with T1-T2 prostate cancer were treated with ADT. 4 The data from the Korean National Health Insurance showed that 49.9% of newly diagnosed prostate cancer patients received ADT, and the ratio of ADT compared with surgery or radiotherapy was maximized in patients aged ≥75 years. 5 Precise predictions can help patients to plan for their future. A number of risk classifications already exist, but their accuracy varies according to the patient cohort. The D'Amico risk classification was introduced in 1988, and their cohort included patients who underwent radical prostatectomy, external beam radiation or implant for localized prostate cancer. 6 After modification of the D'Amico risk classification, the NCCN annually determined the risk classification to identify the optimal primary treatment option. 7 Another method of risk classification is the CAPRA score that includes additional criteria regarding patient age and percentage of positive biopsy cores. 8 Their cohort included cases of primary radical prostatectomy, but did not include patients who received primary radiotherapy or primary ADT. We have included the Glass model to classify metastatic prostate cancer risk. 9, 10 To evaluate prognosis in the high number of advanced disease patients who received primary ADT, the J-CAPRA was designed. [11] [12] [13] [14] [15] We attempted to confirm the efficacy of previous risk classifications, and develop a reliable and simple model to predict oncological outcomes in patients who underwent primary ADT.
Methods

Ethics statement
This study was approved by the ethics board of Asan Medical Center. There was no need for written consent, as patient data were anonymized before analysis. The research process was carried out according to the ethics of the Helsinki Declaration.
Patient enrollment
A retrospective review was carried out to identify prostate cancer patients who received primary ADT at the Asan Medical Center between 2008 and 2012. In total, 602 patients were included in the KCS-prostate database. Patients who underwent radical prostatectomy (n = 218) or definitive radiation therapy (n = 137) after ADT were excluded. Clinical data for age, BMI, and past medical history including Charlson Comorbidity Index, serum PSA levels, prostate volume, clinical prostate cancer TNM stage, GS and core-related variables at biopsy were collected. Patients were treated with luteinizing hormone-releasing hormone agonist or anti-androgenic agent therapy. Patients were followed up using serum PSA, computed tomography or bone scan. CRPC was defined as a rise of PSA in two consecutive measurements taken at least 1 week apart; PSA was required to be ≥2 ng/mL above the nadir value despite castrate levels of testosterone (serum testosterone <50 ng/dL). Radiological progression was assessed using the Prostate Cancer Clinical Trials Working Group 2 guidelines. 16 CSS and OS were calculated from the diagnosis of prostate cancer to death. CSS was attributed to progressive metastatic CRPC.
Statistical analysis
We investigated the CRPC-free survival using the Cox proportional hazards regression model. Based on the coefficients of the variables in the multivariate model, a number of points were assigned to each variable. The point that was arranged by patients' characteristics was totaled to give a risk score. We divided patients into low, intermediate and high KCSprostate risk groups according to their total score. CRPC-free survival, CSS and OS were estimated using the KaplanMeier method with a log-rank test according to risk groups. We calculated the estimated cumulative proportions of CRPC, cancer-specific death and death at 1, 3 and 5 years. Patients were stratified into categories according to the NCCN, 7 .0 ng/mL (IQR 10.9-148.5). GSs were ≥9 in 259 cases (43.0%). CAB was used in the majority of patients (83.1%); palliative radiation therapy was used in 62 (10.3%) patients. During the median follow-up period of 40.7 months, we observed 239 patients (39.7%) with CRPC, 202 patients (33.6%) with radiological progression and 327 patients (54.3%) who died. The first treatments after CRPC were docetaxel (40.2%), prolonged ADT (25.9%), estramustine (13.0%), enzalutamide (5.4%) and abiraterone (4.6%).
Each risk classification stratified our cohort into various proportions according to age (Fig. 1 ). In the NCCN risk group, high-and very high-risk ratios increased in the older age group, but the metastatic ratio decreased in the older age group. In the J-CAPRA classification, the majority of patients were in the intermediate risk group (66.3%). In the Glass model, the good risk group (55.0%) made up the majority. In all risk classification models, patients aged ≤60 years showed worse risks than those aged >75 years.
The multivariate Cox model showed that the initial PSA level (>40 ng/mL vs ≤40 ng/mL; HR 1.493, 95% CI 1.082-2.061; P = 0.0147), GS (≥9 vs <9; HR 2.103, 95% CI 1.574-2.809; P < 0.0001), regional lymph node metastasis (HR 1.737, 95% CI 1.254-2.406; P = 0.0009), non-regional lymph node metastasis (HR 2.272, 95% CI 1.559-3.310; P < 0.0001), bone metastasis (HR 2.688, 95% CI 1.958-3.688; P < 0.0001) and visceral metastasis (HR 2.130, 95% CI 1.250-3.628; P = 0.0054) were significant predictive factors for CRPC (Table 2) . Each significant variable was assigned 1 point. The points were totaled to give a score for each patient that ranged from 0 (best prognosis) to 6 (worst prognosis). Patients were divided into three groups (low risk: 0; intermediate risk: 1-2; and high risk: ≥3) according to their KCS-prostate score.
Each risk classification showed well-stratified Kaplan-Meier graphs (Fig. 2) . The three risk groups differed from each other in CRPC-free survival, CSS and OS (all P < 0.0001). Table 3 presents the estimated cumulative proportions of CRPC, cancer-specific death and death. The probabilities of CRPC at 1, 3 and 5 years were predicted to be 1.5%, 7.3% and 10.3% in the low risk group; 13 The c-indices of KCS-prostate risk classification were 0.7242 (SE 0.0187) for CRPC-free survival, 0.7036 (SE 0.0213) for CSS and 0.5890 (SE 0.0159) for OS in the present cohort (Table 4) . The c-indices of NCCN risk were 0.6969 (P = 0.0213) for CRPC, 0.6758 (P = 0.0408) for CSS and 0.5723 (P = 0.0905) for OS. J-CAPRA showed cindices of 0.6435 (P < 0.0001) for CRPC, 0.6321 (P = 0.0187) for CSS and 0.5696 (P = 0.1562) for OS. In addition, the Glass model showed c-indices of 0.7045 (P = 0.1227) for CRPC, 0.6842 (P = 0.3915) for CSS and 0.5813 (P = 0.7200) for OS. Table 5 shows various risk classification models.
Discussion
Initially, we tried to validate the J-CAPRA model, but it was difficult to obtain the risk because of the complexity of the score composition. Therefore, we attempted to develop a simple model of risk prediction using our cohort receiving primary ADT. Accordingly, we established the KCS-prostate risk classification, which incorporates the variables of initial PSA level, GS, N1 stage, and non-regional lymph node, bone and visceral metastasis. Because of the similarity of the included variables, the KCS-prostate classification might be thought of as modified J-CAPRA criteria. According to the KCS-prostate risk classification, the 5-year estimated cumulative proportions of CRPC were 10%, 50% and 80%, and the proportions of cancer-specific death were 6%, 20% and 50% in the low, intermediate and high-risk groups, respectively. The advantages of this classification are that it is relatively simple and easy to apply in a clinical situation. The KCSprostate risk classification does not require clinicians to consult a paper reference table or computer program. We can predict prognosis using just six variables that each have a single criterion. In comparison, the J-CAPRA risk classification is a relatively complex system that has five variables, each of which can have up to 3 points. In addition, the KCS-prostate model gives proper c-index values for predictive accuracy, showing greater model reliability, for both CRPC-free survival and CSS, and thus can discriminate accurately without complex calculation. The D'Amico and CAPRA classifications are based on cohorts that consisted of patients who underwent radical prostatectomy, the Glass model is targeted at metastatic prostate cancer patients, and the J-CAPRA classification was surveyed in patients receiving primary ADT. The KCS-prostate risk classification can give patients with locally advanced or metastatic disease a reliable prediction of outcome after primary ADT. Patients with an expected poor prognosis can then participate in clinical trials or plan to receive more aggressive treatment. PSA criterion is included as a factor in other classification models, including the J-CAPRA (PSA criteria 20, 100 and 500 ng/mL) and Glass (PSA criteria 65 ng/mL) models. In the present model, a criterion of initial PSA >40 ng/mL was selected based on the rounded median value. The pretreatment PSA level is widely reported as a prognostic factor for prediction of CRPC in other studies about primary ADT. 11, 17 A GS ≥9 was selected in the present study using multivariate analysis. GSs ≥9 showed worse distant metastatic-free survival and CSS than GSs ≤8 in a study of high-risk patients treated with external beam radiotherapy. 18 In the present data, all patients who had GS ≥9 had a Gleason pattern 5 as their primary or secondary pattern. Cocchiola et al. studied the relationship between GS and various molecular pathways using human prostate cancer cells. 19 An increase in expression for MMP2 (factor involved in tumor invasion), BIRC5 (anti-apoptotic protein), the CRP gene (inflammatory state) and SOD2 (oxidative state) was observed in samples that had a high GS. 19 In addition, downregulation of the SRD5A2 gene in samples with GS 9 was associated with the progression of aggressive hormone-independent cells. 19 Clinical T stage was not a significant factor in multivariate analysis of the present results. These trends were similar to those observed in a study by Chad et al. that included 4654 patients with metastatic prostate cancer. 20 In that study, younger age, lower PSA level and lower GS were predictors for CSS and OS. 20 The present cohort mostly comprised cases of advanced prostate cancer, of which approximately half were N1 or M1 stage disease. A potential explanation for the non-significance of T stage might be that most patients who were selected for primary ADT had non-localized disease, worse comorbidity or old age. These specific conditions could not be generalized in whole prostate cancer disease. Hsiao et al. compared three groups of cT4N0M0, N1 and M1, and showed significant differences between T4 versus M1 and N1 versus M1 disease. 21 M1 stage can receive a maximum of 3 points in the risk model, according to the disease status of the non-regional lymph nodes, bones and viscera. In the J-CAPRA risk model, they also assigned M1 stage the relatively high number of 3 points, due to a high HR. In the recently published study of metastatic hormone-na€ ıve prostate cancer (CHAARTED trial), visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis was associated with poor prognosis. 22 We also add 1 point in cases of visceral metastasis. M1 stage showed a strong association with early progression, and circulating tumor cells were detected more frequently in M1 patients. 23 In localized prostate cancer, circulating tumor cells did not show a significant correlation with pathological T stage, and no studies have proven that circulating tumor cells predict unfavorable prognosis. 24 However, in metastatic prostate cancer, the presence or number of circulating tumor cells indicate worse prognosis. 25 One small sequencing study showed that lymph node metastasis was phylogenetically more closely associated with circulating tumor cells. 26 The presence of circulating tumor cells might explain lymph node metastasis or distant metastasis. If a simple, feasible and cheap method to detect circulating tumor cells is developed, like PSA testing, it is likely that the prognostic factors will change.
The present study had several limitations. First, the KCSprostate database included patients treated with primary ADT on the basis of clinical judgment. Furthermore, a small number of patients refused local therapy. This could result in data with heterogeneous characteristics; however, this is reflective of the real-world situation. Second, this study was based on a retrospective analysis, so we could not collect data on new variables, such as simple risk classification without additional examinations or complex reference tables. Although a small cohort of 168 patients was evaluated, a model including ALP and albumin levels was developed. 27 Third, whether patients in the present cohort received continuous or intermittent ADT was not surveyed. However, the initial type of ADT and administration of palliative radiotherapy were not significant factors for CRPC-free survival. Finally, there has been a shift in the treatment paradigm for metastatic prostate cancer, with the CHAARTED and LATITUDE trials highlighting the effectiveness of upfront chemotherapy or secondary hormone regimens. 22, 28 Patients treated with these new therapies are expected to show more favorable oncological outcomes. The Glass and J-CAPRA models were reported in 2003 and 2009, 9, 11 respectively, when life-prolonging agents for CRPC, such as taxanes or new anti-androgens, were limited. Our cohort included docetaxel (40.2%) and new anti-androgens (10.0%) after CRPC. In the near future, prognostic classifications should be re-established.
Primary ADT is one of the most common methods of treatment for advanced prostate cancer, and is sometimes used as treatment for localized prostate cancer. The KCSprostate risk classification, a modified J-CAPRA criterion, is a simple scoring model for predicting oncological outcomes after primary ADT. In the present cohort, this model showed predictive accuracy for CRPC-free survival and CSS comparable with that of other risk classification models. This prognostic model can be helpful to patients and clinicians due to its intuitive nature. We hope that future studies, carried out internationally and on a larger scale, will be able to validate the use of the KCS-prostate risk classification.
